The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Thinkhat attends the Precision Medicine World Conference (PMWC) and unveils the first of its AI-driven healthcare and life science (HLS) p ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

with much better precision, what everyone’s biggest risks are,” Baras says, noting that medicine tends to be more reactive than proactive. “What we’ve proven in health care is, when you ge ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Nintendo has finally revealed its new console, Nintendo Switch 2, and we’ve published the first images in a gallery below. In a Nintendo Switch 2 reveal video published on Thursday, the platform ...

A 34-year-old social media influencer has been accused of torturing her baby daughter and taking photos of her in "immense ... the woman gave medicine to her one-year-old daughter without medical ...

Prime Minister Narendra Modi recently lauded the completion of the ambitious Genome India Project. He unveiled the genome sequencing data of 10,000 Indian nationals, calling it a significant milestone ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

NEW YORK – Biogen is "doubling down" on its drug development efforts in Alzheimer's disease, company President and CEO Christopher Viehbacher said Tuesday at the JP Morgan Healthcare Conference in San ...